Pelvic-floor therapy may be an option for sexual symptoms after breast cancer. Understand the evidence and the role of coordinated menopause care.
On October 23, 2026, ClickOnDetroit published a report on menopause symptoms after breast cancer that emphasized discussion with both an oncologist and a clinician experienced in menopause care. The coverage described pelvic pain and sexual dysfunction that can interfere with intimacy for some breast-cancer patients and survivors.
Its central message was that these concerns belong in a care conversation. The report highlighted pelvic-floor therapy as one possible nonhormonal approach while stressing that hormone-treatment decisions depend on cancer history and current treatment.
For someone unsure whether to mention a change in sexual comfort, that is a useful starting point. The question is not simply whether hormones are available. It is how to discuss the symptom and consider appropriate options without treating intimacy as an afterthought.
ClickOnDetroit’s report draws on clinician commentary about menopause symptoms in breast-cancer patients and survivors. It includes comments from Dr. Rachel Miller, a physical therapist who treats menopause patients, and Dr. Carrie Leff. Its focus is practical care discussion rather than the results of a treatment trial.
A separate source provides a framework for that discussion: the Italian societies’ 2026 recommendations. These address individualized decisions involving the patient and clinicians responsible for gynecological and cancer care. They consider treatment options alongside the circumstances that influence their suitability.
The two sources serve different purposes. The news report brings attention to symptoms that can affect intimacy and names an option worth discussing. The recommendations place symptom care within a broader decision process. Reading them together helps separate a useful clinical question from a claim that one treatment has been established as the answer.
ClickOnDetroit reported that menopause-related pelvic pain and sexual dysfunction can affect intimacy for some people during or after breast-cancer care. The coverage treats these as appropriate subjects for medical discussion rather than concerns that must simply be endured.
That framing matters for the conversation itself. A reader does not need to arrive with a proposed treatment to raise a concern. Describing the change is a starting point; deciding which care options fit belongs in the discussion with clinicians.
Miller told ClickOnDetroit that pelvic-floor therapy may help address pelvic pain and sexual dysfunction. The report presented it as distinct from hormone treatment.
The Italian recommendations also discuss pelvic-floor approaches. They list biofeedback, myofascial release, stretching and dilators among the approaches considered. These names describe possibilities within the care discussion rather than a single standardized treatment.
The useful point is that a conversation about sexual symptoms need not stop at the question of hormone therapy. Pelvic-floor care is another subject that can be raised with the team responsible for assessing the concern.
Leff told ClickOnDetroit: “There’s also many therapies out there for breast cancer patients that may be non-hormonal, and lots of conversations that we can have around it.”
The report also emphasized that hormone-treatment decisions depend on the individual’s cancer history and current treatment. Its message was to bring sexual-health concerns to both an oncologist and a clinician experienced in menopause care.
Taken together, those points shift the focus from finding a single replacement for hormones to discussing the range of options relevant to the person’s situation.
The ClickOnDetroit article offers general care guidance rather than experimental evidence. It reports no treatment outcomes and provides no therapy protocol. It therefore supplies neither a measured benefit nor information about which techniques to use or how often treatment should take place.
The Italian authors characterize their recommendations as evidence-based expert consensus rather than a formal GRADE clinical practice guideline. They also identify an absence of controlled studies specifically examining pelvic-floor therapy in postmenopausal women. That leaves uncertainty about which approaches help particular patients and how much benefit to expect.
These sources do not establish how common the reported symptoms are across all breast-cancer survivors. Nor do they establish that pelvic-floor therapy works equally well across different cancer histories or treatment settings. A clinician’s view that an approach may help is different from a demonstrated treatment effect in a defined study population.
Another important boundary concerns the cause of symptoms. Survivors should not assume that every new sexual or pelvic concern is caused by menopause. The source-supported approach is to assess symptoms in the context of cancer characteristics and current treatment rather than assign an explanation in advance.
The report’s attention to nonhormonal options is consistent with the Italian societies’ recommendations. Those recommendations present moisturizers and lubricants as first-line approaches for menopausal vaginal symptoms. They place other treatment choices within individualized discussions with the care team.
This gives pelvic-floor therapy a place within a broader conversation. Mentioning it does not erase the other approaches in the recommendations. Equally, describing an option as nonhormonal does not by itself establish that it is the right match for a particular concern.
The distinction is useful when reading health coverage. “Nonhormonal” identifies a category. The care discussion still needs to address the symptom being considered and the reasons a particular approach might be relevant. A category name is not the same as a decision.
The Italian recommendations describe shared decision-making involving the patient, gynecologist and treating oncologist. Considerations include cancer characteristics and current endocrine treatment. Symptom severity and the patient’s preferences also belong in that process.
That framework makes the ClickOnDetroit report most useful as an invitation to a fuller discussion. The update draws attention to pelvic-floor care, while the recommendations explain why treatment choices remain individualized.
Sexential’s discussion of menopause-related vaginal discomfort offers broader context for understanding the subject. For a reader with a breast-cancer history, the cancer-specific conversation remains central to decisions about care.
The practical significance is not that readers should select a therapy from a news story. It is that pain and sexual concerns are appropriate topics for coordinated clinical discussion. ClickOnDetroit specifically points to involving both oncology and menopause-care clinicians.
A useful conversation can be organized around questions such as:
These questions do not assume a diagnosis or commit someone to treatment. They keep the discussion focused on the concern and the context needed to evaluate it. They also leave room for the person’s preferences rather than making treatment suitability the only subject.
For readers worried about confidence, it may be more useful to describe what has changed than to search for the correct medical label. A conversation can begin with the concern about comfort or intimacy itself. The reporting supports bringing that concern into care without first deciding what caused it.
Partners also have a place in this discussion without taking over treatment decisions. The reporting supports treating pain and sexual concerns as legitimate subjects for clinical attention. A supportive starting point is to take the concern seriously rather than assume that changes in intimacy must simply be accepted without discussion.
Broader reading on changing sexual needs during perimenopause can help put language around the subject. The purpose is not to fit every experience into the same explanation, but to make room for a clearer conversation about what has changed.
One step today: Write down one change in comfort or intimacy that you want to raise with your oncology or menopause-care clinician.
Reducing intimacy after breast cancer to a single therapy leaves out the wider context that guides Sexential’s evidence-aware writing. For adults aged 35 to 65 who feel less confident about changed sexual experiences, its calm explanations connect biology with everyday life without labelling the reader or prescribing care.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A physician-led explainer puts sexual symptoms, distress and context ahead of assumptions about age, with guidance on desire, discomfort and screening.
A practical guide to sustainable movement, sexual confidence and the evidence on erectile function, without making exercise a test of sexual performance.
A grounded guide for men and couples to understand libido changes through health, stress, medicines and relationship context, without assuming one cause.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
